Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Guidelines in 2024: International Contributions from China

Jianbin Li; Zefei Jiang

doi:10.20892/j.issn.2095-3941.2024.0374

Article Figures & Data

Tables

View popup

Table 1

Some pivotal randomized clinical trials with breast cancer led by China

Trials	Stage	Phenotypes	Experimental groups	Control groups	Primary endpoint	Result of primary endpoint
PEONY	Neoadjuvant	HER2-positive	TH+pertuzumab	TH	pCR	39.3% vs. 21.8%
PHEDRA	Neoadjuvant	HER2-positive	TH+pyrotinib	TH	pCR	41% vs. 22%
PHILA	First-line	HER2-positive	TH+pyrotinib	TH	PFS	24.3 vs. 10.4 months
PHENIX	Second-line	HER2-positive	Pyrotinib+capecitabine	Capecitabine	PFS	11.1 vs. 4.1 months
PHOEBE	Second-line	HER2-positive	Pyrotinib+capecitabine	Lapatinib+capecitabine	PFS	12.5 vs. 6.8 months
cTRIO	Neoadjuvant	TNBC	TP+tislelizumab	–	pCR	56.5%
NeoTennis	Neoadjuvant	TNBC	AC-T+toripalimab	–	pCR	55.7%
SYSUCC-01	Adjuvant	TNBC	Capecitabine	Placebo	5y-DFS	82.8% vs. 73.0%
TORCHLIGHT	First-line	TNBC	T+toripalimab	T	PFS	8.4 vs. 5.6 months
Monarch plus	First-line	HR-positive	Cohort A: AI+abemaciclib Cohort B: F+abemaciclib	Cohort A: AI Cohort B: F	PFS	Cohort A: 14.7 vs. not reached Cohort B: 11.5 vs. 5.6 months
DAWNA-1	Second-line	HR-positive	F+dalpiciclib	F	PFS	15.7 vs. 7.2 months
DAWNA-2	First-line	HR-positive	AI+dalpicclib	AI	PFS	30.6 vs. 18.2 months
ACE	First-line	HR-positive	AI+chidamide	AI	PFS	7.4 vs. 3.8 months

T: taxane; H: trastuzumab; P: carboplatin; AC: by anthracycline with cyclophosphamide; AI: aromatase inhibitor; F: fulvestrant; pCR: pathologic complete remission; PFS: progression-free survival; DFS: disease-free survival; HER2: human epidermal growth factor receptor 2; TNBC: triple-negative breast cancer; HR: hormone receptor.